thalidomide has been researched along with Bladder Cancer in 8 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To understand the effect of Nitazoxanide (NTZ), Rapamycin, Thalidomide, alone and in combination with BCG on bladder cancer (BC) histopathology and programmed death-ligand 1 (PD-L1) and anti-cytotoxic T lymphocyte antigen 4 (CTLA4) expression." | 8.31 | Bladder cancer immunomodulatory effects of intravesical Nitazoxanide, Rapamycin, Thalidomide and Bacillus Calmette-Guérin (BCG). ( Andrade, DL; Jalalizadeh, M; Reis, LO; Salustiano, ACC, 2023) |
| "Thalidomide precipitates were observed when its DMSO solution was added to the culture medium." | 5.42 | Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer. ( Cheng, CC; Chiu, TH; Huang, YT; Lai, PC, 2015) |
| "To understand the effect of Nitazoxanide (NTZ), Rapamycin, Thalidomide, alone and in combination with BCG on bladder cancer (BC) histopathology and programmed death-ligand 1 (PD-L1) and anti-cytotoxic T lymphocyte antigen 4 (CTLA4) expression." | 4.31 | Bladder cancer immunomodulatory effects of intravesical Nitazoxanide, Rapamycin, Thalidomide and Bacillus Calmette-Guérin (BCG). ( Andrade, DL; Jalalizadeh, M; Reis, LO; Salustiano, ACC, 2023) |
| "Thalidomide precipitates were observed when its DMSO solution was added to the culture medium." | 1.42 | Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer. ( Cheng, CC; Chiu, TH; Huang, YT; Lai, PC, 2015) |
| "Lenalidomide is an IMiD® immunomodulatory drug, which may warrant evaluation in urothelial carcinoma (UC)." | 1.40 | The preclinical activity of lenalidomide in indolent urothelial carcinoma. ( Jian, W; Lerner, SP; Levitt, JM; Sonpavde, G, 2014) |
| "Plasmacytoma is a rare B-lymphocyte neoplastic disorder that usually presents as the generalized disease multiple myeloma." | 1.36 | Solitary extramedullary plasmacytoma of the bladder: a case report and literature. ( Egner, JR; Khaliq, W; Konchanin, RP; Sapiente, RA; Uzoaru, I, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrade, DL | 1 |
| Jalalizadeh, M | 1 |
| Salustiano, ACC | 1 |
| Reis, LO | 2 |
| Takama, H | 1 |
| Shibata, T | 1 |
| Ando, Y | 1 |
| Yanagishita, T | 1 |
| Ohshima, Y | 1 |
| Akiyama, M | 1 |
| Watanabe, D | 1 |
| Passos, GR | 1 |
| Camargo, JA | 1 |
| Ferrari, KL | 1 |
| Saad, MJA | 1 |
| de Mattos, AC | 1 |
| Jian, W | 1 |
| Levitt, JM | 1 |
| Lerner, SP | 1 |
| Sonpavde, G | 1 |
| Huang, YT | 1 |
| Cheng, CC | 1 |
| Chiu, TH | 1 |
| Lai, PC | 1 |
| Khaliq, W | 1 |
| Uzoaru, I | 1 |
| Konchanin, RP | 1 |
| Sapiente, RA | 1 |
| Egner, JR | 1 |
| Wilson, SS | 1 |
| Theodorescu, D | 1 |
| Jinesh, GG | 1 |
| Lee, EK | 1 |
| Tran, J | 1 |
| Kamat, AM | 1 |
1 review available for thalidomide and Bladder Cancer
| Article | Year |
|---|---|
Rare bladder tumors: caveat emptor.
Topics: Abnormalities, Drug-Induced; Disease Progression; Female; Humans; Lenalidomide; Male; Multiple Myelo | 2010 |
7 other studies available for thalidomide and Bladder Cancer
| Article | Year |
|---|---|
Bladder cancer immunomodulatory effects of intravesical Nitazoxanide, Rapamycin, Thalidomide and Bacillus Calmette-Guérin (BCG).
Topics: Adjuvants, Immunologic; Administration, Intravesical; Animals; B7-H1 Antigen; BCG Vaccine; CTLA-4 An | 2023 |
Pembrolizumab-induced psoriasis vulgaris successfully treated with apremilast.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antineoplastic Age | 2020 |
Intravesical Thalidomide boosts bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer treatment.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Animals; Apoptosis; BCG Vaccine; Carrier Prote | 2017 |
The preclinical activity of lenalidomide in indolent urothelial carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cerebrosides; Drug Screening Assays, | 2014 |
Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer.
Topics: Animals; Apoptosis; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Gene Expressi | 2015 |
Solitary extramedullary plasmacytoma of the bladder: a case report and literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cystoscopy; Dexamethasone; Humans; Len | 2010 |
Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; BCG Vaccine; Blotting, Western; | 2013 |